AU · rank #17 · 2026-09-09
IMCD
AMSTERDAM · EUR · $6.83B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.633 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 8 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +17.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +9.82% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $103.20 |
| Market cap (USD) | $6.83B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global distributor and formulator of specialty chemicals and ingredients, operating across diversified end markets [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
A strong Q2 2026 earnings recovery, featuring 11% organic EBITDA growth and a 29% jump in H1 free cash flow, validates the model's 9.18% 30-day EPS revision and 17.69% analyst upside signal [RECENT_DEVELOPMENTS].
Material risks
- 1Disintermediation of IMCD’s relationship-driven model if key suppliers or customers choose to internalize distribution and technical formulation capabilities [TOP_RISKS].
- 2Margin dilution and integration friction from structurally lower-margin acquisitions, which led to a 70 basis point year-over-year gross margin decline in H1 2026 [COMPETITIVE_POSITION, TOP_RISKS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.